CAJ | 학술논문

目的评估Hyper-CVAD/MA强化方案治疗28例中国人T细胞性和侵袭性/高度侵袭性B细胞性非霍奇金淋巴瘤患者的有效性和安全性.方法回顾性分析28例2005年1月至2008年9月用Hyper-CVAD/MA方案治疗的初治或复治的B细胞或T细胞非霍奇金淋巴瘤患者的有效性和安全性.结果在27例可评价疗效的包括T细胞和B细胞淋巴瘤的病例中,有效率是70.4%;在13例可评价疗效的B细胞淋巴瘤中,有效率是84.6%.27例患者均发生Ⅲ度或Ⅳ度的骨髓抑制,有2例治疗相关死亡.结论 Hypor-CVAD/MA方案治疗中国人T细胞性和侵袭性/高度侵袭性B细胞性非霍奇金淋巴瘤,有效率高,但毒副作用也显著,剂量需要进一步摸索.
목적 평고Hyper-CVAD/MA강화방안치료28례중국인T세포성화침습성/고도침습성B세포성비곽기금림파류환자적유효성화안전성.방법 회고성분석28례2005년1월지2008년9월용Hyper-CVAD/MA방안치료적초치혹복치적B세포혹T세포비곽기금림파류환자적유효성화안전성.결과 재27례가평개료효적포괄T세포화B세포림파류적병례중,유효솔시70.4%;재13례가평개료효적B세포림파류중,유효솔시84.6%.27례환자균발생Ⅲ도혹Ⅳ도적골수억제,유2례치료상관사망.결론 Hypor-CVAD/MA방안치료중국인T세포성화침습성/고도침습성B세포성비곽기금림파류,유효솔고,단독부작용야현저,제량수요진일보모색.
Objective To evaluate the efficacy and safety of the hyper-CVAD/MA regimen as an intensified treatment option for 28 T cell and aggressive/highly aggressive B cell NHL in Chinese patients. Methods Clinical data of 28 NHL patients treated with hyper-CVAD/MA regimen from Jan 2005 to Sep 2008 were retrospectively analyzed. Results 27 NHL patients were available for the efficacy analysis, with a response rate of 70.4 %. For the 13 B cell lymphoma cases, the response rate was 84.6 %. The main toxicity was Grade Ⅲ or Grade Ⅳ myelosuppression in all cases and 2 treatment related deaths. Conclusion Hyper-CVAD/MA regimen had a high response rate in T cell and aggressive /highly aggressive B cell NHL lymphoma, companied by significant toxicity when treating Chinese patients. Further clinical practices are needed to pick up a suitable dose which can balance efficacy and safety.